PI-1840

CAT: 0804-HY-12286-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-12286-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PI-1840 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α[1][2].
CAS Number
[1401223-22-0]
UNSPSC
12352005
Hazard Statement
H317-H319
Target
Apoptosis; Autophagy; Bcl-2 Family; Caspase; NF-κB; PARP; Proteasome
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PI-1840.html
Purity
98.78
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL
Smiles
O=C(N(C(C)C)CC1=NC(C2=CC=CN=C2)=NO1)COC3=CC=C(CCC)C=C3
Molecular Formula
C22H26N4O3
Molecular Weight
394.47
Precautions
P261-P264-P272-P280-P302+P352-P305+P351+P338-P362+P364-P501
References & Citations
[1]Kazi A, et, al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem. 2014 Apr 25;289 (17) :11906-11915.|[2]Chen Y, et, al. Non covalent proteasome inhibitor PI 1840 induces apoptosis and autophagy in osteosarcoma cells. Oncol Rep. 2019 May;41 (5) :2803-2817.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products